Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)

Contributed by: Business Wire

Logo

Tags

Health

Clinical Trials

Research

Science

Pharmaceutical

Optical

Biotechnology

NJCTTQ, NTB003, IND approval

More Like This

Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences

Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors

Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform

(Graphic: Business Wire)

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody